Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph M Connors

Showing results (131-140 of 302) with videos related to

Pageof 31
Sort By:
Blood|November 26, 2008
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survivalNathalie A Johnson, Merrill Boyle, Ali Bashashati, et al.
Leukemia & Lymphoma|October 17, 2017
Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, CanadaLauren J Lee, Cynthia L Toze, Steven J T Huang, et al.
British Journal of Haematology|July 23, 2016
Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk modelRoopesh Kansara, Diego Villa, Alina S Gerrie, et al.
Virchows Archiv : an International Journal of Pathology|November 27, 2016
Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphomaSamantha Kendrick, Lisa M Rimsza, David W Scott, et al.
Leukemia & Lymphoma|July 29, 2020
Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experienceAhmed Sawas, Helen Ma, John Kuruvilla, et al.
Blood|September 8, 2012
Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphomaChristian Steidl, Arjan Diepstra, Tang Lee, et al.
Leukemia & Lymphoma|June 24, 2022
Outcomes after initial refusal of curative treatment in patients with classic Hodgkin lymphomaManik Chahal, Anna Hayden, Kerry J Savage, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 6, 2007
Genetic variation in H2AFX contributes to risk of non-Hodgkin lymphomaKaren L Novik, John J Spinelli, Amy C Macarthur, et al.
Leukemia & Lymphoma|September 2, 2015
Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with classical Hodgkin lymphomaEdward G Brooks, Joseph M Connors, Laurie H Sehn, et al.
Blood|February 15, 2013
The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphomaBarbara Meissner, Robert Kridel, Raymond S Lim, et al.
Pageof 31

Showing results (131-140 of 302) with videos related to

Sort By:
Pageof 31
Blood|November 26, 2008
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survivalNathalie A Johnson, Merrill Boyle, Ali Bashashati, et al.
Leukemia & Lymphoma|October 17, 2017
Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, CanadaLauren J Lee, Cynthia L Toze, Steven J T Huang, et al.
British Journal of Haematology|July 23, 2016
Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk modelRoopesh Kansara, Diego Villa, Alina S Gerrie, et al.
Virchows Archiv : an International Journal of Pathology|November 27, 2016
Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphomaSamantha Kendrick, Lisa M Rimsza, David W Scott, et al.
Leukemia & Lymphoma|July 29, 2020
Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experienceAhmed Sawas, Helen Ma, John Kuruvilla, et al.
Blood|September 8, 2012
Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphomaChristian Steidl, Arjan Diepstra, Tang Lee, et al.
Leukemia & Lymphoma|June 24, 2022
Outcomes after initial refusal of curative treatment in patients with classic Hodgkin lymphomaManik Chahal, Anna Hayden, Kerry J Savage, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 6, 2007
Genetic variation in H2AFX contributes to risk of non-Hodgkin lymphomaKaren L Novik, John J Spinelli, Amy C Macarthur, et al.
Leukemia & Lymphoma|September 2, 2015
Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with classical Hodgkin lymphomaEdward G Brooks, Joseph M Connors, Laurie H Sehn, et al.
Blood|February 15, 2013
The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphomaBarbara Meissner, Robert Kridel, Raymond S Lim, et al.
Pageof 31